Presenters
Susanna Naggie, MD, MHS
Duke University School of MedicineOverview
Assessment of Needs
The IAS–USA offers this state-of-the-art activity on the evolving challenges of managing HCV disease as part of a nationwide continuing medical education (CME) effort for physicians.
With 8 FDA approved treatment regimens for chronic HCV, there are many great options for all oral therapy and access has been extended to the majority of special populations. This talk will review the approach to starting HCV therapy and discuss decision points for choosing the right regimen for each patient.
Learning Objectives
Upon completion of this webinar, learners will be able to:
- Discuss pre-treatment assessments and considerations in HIV and HCV
- Discuss differences in DAA approvals and recommendations
- Discuss ongoing challenges and unmet needs in HCV
Registration
Who Should Attend
This webinar is designed for physicians who have a good understanding of the basics of HCV transmission, testing, and management, and have managed HCV infection in at least 5 patients.
This activity is also relevant for registered nurses, PharmDs, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Wednesday, August 29, 2018, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”
Dr Naggie has received research support from AbbVie, Gilead Sciences, Inc, Janssen Therapeutics, and Tacere, and served on an events adjudication committee for Bristol-Myers Squibb. (Updated 08/28/2018)
Continuing Education Credits
CME Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credits
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
This program is approved for 1.25 hours of pharmacotherapy credit.
Pharmacy Credits
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.25 hours (0.125 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-18-227-L02-P
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors
PLATINUM SUPPORTER
Gilead Sciences, Inc
BRONZE SUPPORTER
AbbVie
ADDITIONAL SUPPORT
Merck
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.